These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 24796150

  • 1. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Ueno H, Nakazato M.
    Nihon Naika Gakkai Zasshi; 2014 Mar 10; 103(3):753-9. PubMed ID: 24796150
    [No Abstract] [Full Text] [Related]

  • 2. Recent advancements in drug treatment of obesity.
    Carter R, Mouralidarane A, Ray S, Soeda J, Oben J.
    Clin Med (Lond); 2012 Oct 10; 12(5):456-60. PubMed ID: 23101148
    [Abstract] [Full Text] [Related]

  • 3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S.
    JAMA; 2016 Jun 14; 315(22):2424-34. PubMed ID: 27299618
    [Abstract] [Full Text] [Related]

  • 4. Overview of new antiobesity drugs.
    Hainer V.
    Expert Opin Pharmacother; 2014 Oct 14; 15(14):1975-8. PubMed ID: 25100293
    [Abstract] [Full Text] [Related]

  • 5. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S, Dear A, Cowley MA.
    Obes Res Clin Pract; 2017 Oct 14; 11(5):501-521. PubMed ID: 28818558
    [Abstract] [Full Text] [Related]

  • 6. Tolerability and safety of the new anti-obesity medications.
    Hainer V, Aldhoon-Hainerová I.
    Drug Saf; 2014 Sep 14; 37(9):693-702. PubMed ID: 25096956
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug treatment of obesity: current status and future prospects.
    Kakkar AK, Dahiya N.
    Eur J Intern Med; 2015 Mar 14; 26(2):89-94. PubMed ID: 25634851
    [Abstract] [Full Text] [Related]

  • 9. Medications for Obesity: A Review.
    Gudzune KA, Kushner RF.
    JAMA; 2024 Aug 20; 332(7):571-584. PubMed ID: 39037780
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA.
    Endocrinol Nutr; 2014 Dec 20; 61(10):501-4. PubMed ID: 25434595
    [No Abstract] [Full Text] [Related]

  • 12. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K, Braverman-Panza J.
    J Fam Pract; 2016 Jul 20; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [Abstract] [Full Text] [Related]

  • 13. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE, Gadde KM.
    Drugs Today (Barc); 2011 Dec 20; 47(12):903-14. PubMed ID: 22348915
    [Abstract] [Full Text] [Related]

  • 14. Pharmacotherapy for obesity: What you need to know.
    Bersoux S, Byun TH, Chaliki SS, Poole KG.
    Cleve Clin J Med; 2017 Dec 20; 84(12):951-958. PubMed ID: 29244650
    [Abstract] [Full Text] [Related]

  • 15. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B, Mancini MC.
    Expert Opin Drug Saf; 2017 Jan 20; 16(1):27-39. PubMed ID: 27732121
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phentermine and topiramate extended release (Qsymia™): first global approval.
    Cameron F, Whiteside G, McKeage K.
    Drugs; 2012 Oct 22; 72(15):2033-42. PubMed ID: 23039320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.